Clinical trials: Stage III Follicular Lymphoma
Lymphoma
Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00003356
- Testing
- aldesleukin, rituximab
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University of Rochester
Lymphoma
Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab and galiximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00117975
- Testing
- galiximab, rituximab
- Where
- 68 sites in United States
- Volunteers
- 62 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lymphoma
Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00290667
- Testing
- pegfilgrastim, rituximab, cyclophosphamide
- Where
- 338 sites in Czechia, France and 7 more
- Volunteers
- 586 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
Relapsed Follicular Lymphoma
A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)
This is a Phase III, multicenter, open-label, randomized and controlled study to compare the efficacy of a consolidation therapy with RIT versus ASCT in patients with FL in CR or PR after second or third line chemotherapy…
- Trial name
- NCT01827605
- Testing
- ZEVALIN, BEAM
- Where
- 38 sites in Italy
- Volunteers
- 159 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Relapsed/Refractory Follicular Lymphoma
IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma
This study is a randomized, controlled, double-blind, multicenter, phase III clinical study to evaluate the efficacy of IMM0306 (Amulirafusp Alfa)in combination with lenalidomide versus placebo in combination with lenalidomide in…
- Trial name
- NCT07355283
- Testing
- IMM0306 2.0 mg/kg, Lenalidomide 20 mg
- Where
- China
- Volunteers
- 198 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Leukemia, Lymphoma
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00003402
- Testing
- carmustine, cisplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Maryland, Baltimore
Lymphoma
SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00004031
- Testing
- rituximab, CHOP regimen, carmustine
- Where
- 15 sites in United States, Canada
- Volunteers
- 397 people
- Sponsor
- SWOG Cancer Research Network
Lymphoma, Small Intestine Cancer
Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma
RATIONALE: Interferon alfa may interfere with the growth of the cancer cells and slow the growth of non-Hodgkin's lymphoma. PURPOSE: Phase II trial to study the effectiveness of interferon alfa-2b in treating patients who have…
- Trial name
- NCT00006039
- Testing
- pegylated interferon alfa
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Endometrial Cancer
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
RATIONALE: Metformin and temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Breast Cancer, Endometrial Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00659568
- Testing
- metformin hydrochloride, temsirolimus
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- London Health Sciences Centre
Cancer
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
RATIONALE: White blood cells that have been treated in the laboratory may kill cells that are infected with cytomegalovirus. PURPOSE: This phase I trial is studying how well cytotoxic T cells work in treating patients who have…
- Trial name
- NCT00769613
- Testing
- cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Milton S. Hershey Medical Center
Breast Cancer, Leukemia
High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00060255
- Testing
- busulfan, carboplatin, carmustine
- Where
- United States
- Volunteers
- 451 people
- Sponsor
- Roswell Park Cancer Institute
Leukemia, Lymphoma
Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Monoclonal antibodies such as daclizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00006350
- Testing
- daclizumab, therapeutic allogeneic lymphocytes, mycophenolate mofetil
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
RATIONALE: MP470 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying the side effects and best dose of MP470 in treating patients with unresectable…
- Trial name
- NCT00504205
- Testing
- multitargeted receptor tyrosine kinase inhibitor MP470, laboratory biomarker analysis, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Follicular Lymphoma
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
This study is a phase III, randomized, open-label, international, multicenter, interventional trial, designed to compare the efficacy and safety of mosunetuzumab in combination with lenalidomide versus anti-CD20 monoclonal…
- Trial name
- MorningLyte (NCT06284122)
- Testing
- Mosunetuzumab, Lenalidomide, Rituximab
- Where
- 111 sites in Austria, Belgium and 5 more
- Volunteers
- 790 people
- Sponsor
- The Lymphoma Academic Research Organisation
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
This phase Ib/II trial is aimed at studying the combination of a drug named Selinexor (selective inhibitor of nuclear export) in combination with standard therapy for B cell Non-Hodgkin's lymphoma called R-CHOP.
- Conditions
- Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma, Recurrent Follicular Lymphoma
- Trial name
- NCT03147885
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma
Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing…
- Trial name
- NCT00028717
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- 13 sites in Netherlands
- Volunteers
- 400 people
- Sponsor
- Commissie Voor Klinisch Toegepast Onderzoek
Leukemia, Lymphoma
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00423826
- Testing
- Busulfan, Cytarabine, Fludarabine phosphate
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Leukemia, Lymphoma
Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma
RATIONALE: Giving chemotherapy drugs, such as fludarabine and cyclophosphamide, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00006252
- Testing
- fludarabine phosphate, Cyclophosphamide, PBSC
- Where
- 19 sites in United States
- Volunteers
- 47 people
- Sponsor
- Cancer and Leukemia Group B